Argo has advised the founders of P95 in relation to the investment by Ampersand Capital Partners
In the first half of 2023, Argo has advised the founders of P95, a global provider of epidemiology and clinical research solutions, in relation to the investment by Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the life science and healthcare sectors. Ampersand’s investment in P95 is intended to support the growth of P95’s core business and fund the expansion of its CRO services supporting the vaccine and infectious disease end-markets.